hepatic encephalopathy/diarrhea

BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

TECHNICAL FIELD The present invention relates to polymorphic forms of Rifaximin and to methods for their preparation. BACKGROUND Rifaximin (1) is a non-aminoglycoside semi-synthetic, nonsystemic antibiotic derived from Rifamycin, useful for the treatment of traveler's diarrhea in adults and in

TECHNICAL FIELD The present invention relates to polymorphic forms of Rifaximin and to methods for their preparation. BACKGROUND Rifaximin (1) is a non-aminoglycoside semi-synthetic, nonsystemic antibiotic derived from Rifamycin, useful for the treatment of traveler's diarrhea in adults and in

FIELD OF THE INVENTION The present invention relates to 5-ASA derivatives and methods of treating diseases therewith. BACKGROUND OF THE INVENTION Many people suffer from inflammatory bowel disease (IBD). TRD is a generic term used to refer to two inflammatory diseases, ulcerative colitis and Crohn's